Moderna

One stock that has been on an upward trajectory since the outbreak of the COVID-19 pandemic is Moderna Inc (NASDAQ: MRNA), a clinical-stage mRNA company. The Cambridge, Massachusetts-based company first announced a collaboration with the National Institute of Allergy and Infectious Diseases to develop a COVID-19 vaccine on  Jan. 23, and since then the stock…

Moderna's stock was surging Friday after the biotech company announced it has received as much as $483 million in federal funding to accelerate development of a coronavirus vaccine.Shares of the Cambridge, Massachusetts-based firm opened more than 12% higher to around $46. During Thursday's session, the stock hit an intraday all-time high of $41.55.Moderna CEO Stephane Bancel…

MRNA) has announced a $483 million government award to fund manufacturing scale-up and the development of the company’s SARS-CoV-2 vaccine mRNA-1273 to FDA licensure." data-reactid="12" type="text">Biopharma Moderna Inc (MRNA) has announced a $483 million government award to fund manufacturing scale-up and the development of the company’s SARS-CoV-2 vaccine mRNA-1273 to FDA licensure.The NIH-led Phase 1…

Moderna (NASDAQ:MRNA) +10.5% after-hours on news it will receive up to $483M from the U.S. government to accelerate development of a COVID-19 vaccine. The company says the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services will fund development of the mRNA-1273 vaccine candidate to licensure with the Food…

April 16 (Reuters) - Moderna Inc said on Thursday that it received a $483 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its vaccine candidate for the novel coronavirus.The experimental vaccine is being tested in an early-stage trial conducted by the U.S. National Institutes of Health and…